MAAT — Maat Pharma SA Income Statement
0.000.00%
Last trade - 00:00- €124.02m
- €116.49m
- €4.52m
Annual income statement for Maat Pharma SA, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.972 | 1.43 | 2.23 | 3.22 | 4.52 |
| Cost of Revenue | |||||
| Gross Profit | 0.806 | 1.09 | 1.66 | 1.97 | 3.12 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 9.87 | 15 | 22.2 | 31.6 | 34.3 |
| Operating Profit | -8.89 | -13.6 | -19.9 | -28.4 | -29.7 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -9.02 | -13.7 | -19.7 | -28.9 | -31.1 |
| Net Income After Taxes | -9.02 | -13.7 | -19.7 | -28.9 | -31.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -9.02 | -13.7 | -19.7 | -28.9 | -31.1 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -9.02 | -13.7 | -19.7 | -28.9 | -31.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.912 | -1.39 | -1.73 | -2.21 | -1.95 |
| Dividends per Share |